| Study ID | Sample | CM syndrome | Intervention | Controlled | Couse | Adverse event | Outcome measures |
| Fang and Shi, 2006 [9] | T: 20/18 C: 20/17 | NS | MDD | Aminophylline 0.25 g qd, Methylprednisolone 80 mg q12h, Cefoperazone and Sulbactam 2 g q12h, Mucosolvan 75 mg q12h | 5D | NS | BGA, DMV | Fu, 2010 [10] | T: 30/30 C: 30/30 | SPHOL | MDD | Conventional treatment | 9D | NS | PF | Guo and Liang, 2011 [11] | T: 60/60 C: 60/60 | SPHOL | MDD | Mucosolvan 60 mg and conventional treatment | 14D | NS | ER | Guo and Zhang, 2008 [12] | T: 30/30 C: 30/30 | NS | MDD | Conventional treatment | 7D | NS | PF, BGA, ER | Li, 2009 [13] | T: 29/29 C: 27/27 | SPHOL | Tongsai granule 6 g tid | Aminophylline 0.5 g, antibacterial | 15D | NS | Inflammation factor | Li et al., 2003 [14] | T: 60/60 C: 60/60 | SPHOL | MDD | Conventional treatment | 12D | NS | ER | Li, 2006 [15] | T: 30/30 C: 30/30 | SPHOL | MDD | Cefaclor capsules 0.25 g tid, Azithromycin tablets 0.5 g, Mucosolvan 30 mg tid. | 14D | YSE | PF, BGA, ER | Liang, 2011 [16] | T: 30/30 C: 30/30 | NS | MDD | Conventional treatment | 15D | NS | PF, ER | Liu et al., 2002 [17] | T: 25/25 C: 25/25 | NS | MDD | Conventional treatment | 12D | NS | Offline success rate | Lu, 2010 [18] | T: 21/21 C: 21/21 | SPHOL | MDD | Conventional treatment | 10D | NS | PF, BGA, ER | Mao, 2010 [19] | T: 52/52 C: 48/48 | NS | Tongfupaiqi mixture | Conventional treatment | 14D | YES | PF | Meng, 2012 [20] | T: 30/30 C: 30/30 | SPHOL | MDD | Conventional treatment | 7D | NS | PF, ER | Pang, 2009 [21] | T: 42/42 C: 40/40 | SPHOL | MDD | Conventional treatment | 7D | NS | BGA | Peng and Li, 2009 [22] | T: 30/30 C: 30/30 | SPHOL | MDD | Conventional treatment | 14D | NS | ER | Shi et al., 2010 [23] | T: 50/38 C: 30/20 | NS | MDD | Conventional treatment | 28D | NS | DMV | Zhang, 2011 [24] | T: 32/32 C: 30/30 | SPHOL | MDD | Conventional treatment | 7D | NS | PF, ER |
|
|